FIELD: biotechnology.
SUBSTANCE: to consideration is presented a vaccine composition used for performing preventive, metaphylactic or therapeutic treatment of infection caused by Streptococcus suis, in swine and in humans, containing an effective amount of at least one protein or at least one vector, and at least a pharmaceutical carrier, diluent or adjuvant.
EFFECT: this vaccine composition is used in preventive, metaphylactic or therapeutic treatment of infections caused by Streptococcus suis in swine or humans.
16 cl, 6 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| MUTANT NITRILE HYDRATASE, NUCLEIC ACID WHICH ENCODES SAID MUTANT NITRILE HYDRATASE, EXPRESSION VECTOR AND TRANSFORMANT CONTAINING SAID NUCLEIC ACID, METHOD OF PRODUCING SAID MUTANT NITRILE HYDRATASE AND METHOD OF PRODUCING AMIDE COMPOUND | 2017 |
|
RU2736086C1 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
